These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9561021)

  • 21. Cefodizime once daily in the treatment of lower respiratory tract infections.
    Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
    Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis.
    Paster RZ; McAdoo MA; Keyserling CH; Nemeth MA; Tack KJ; Griffin TJ
    Int J Clin Pract; 2000 Jun; 54(5):293-9. PubMed ID: 10954955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Position of ceftazidime in respiratory diseases.
    Ando' F; Girbino G; Ferrara F
    Drugs Exp Clin Res; 1985; 11(6):369-72. PubMed ID: 3915288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J; Profant M; Kostrica R; Waskin H
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD)].
    Burgel PR
    Med Mal Infect; 2006; 36(11-12):706-17. PubMed ID: 16839731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bronchopulmonary infection due to Branhamella catarrhalis in patients with obstructive lung disease].
    Wu LB
    Zhonghua Jie He He Hu Xi Za Zhi; 1990 Dec; 13(6):328-30, 378. PubMed ID: 2128216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronokinetics of ceftazidime after intramuscular administration to dogs.
    Monfrinotti A; Ambros L; Montoya L; Prados AP; Rebuelto M
    Chronobiol Int; 2010 May; 27(3):549-59. PubMed ID: 20524800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of ceftazidime in the treatment of severe localized and systemic infections.
    Gabrielli GB; Corrocher R; De Sandre G
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):167-9. PubMed ID: 6370875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.
    Sohn C; Pitkin D; Grappel S; Zajac I; Actor P; Alexander F; Lentnek A; Wikler M; Stote R; Dubb J
    Clin Ther; 1984; 6(4):560-70. PubMed ID: 6467282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative clinical evaluation of ceftriaxone in treating lower respiratory tract infections.
    Abbate GF; Alagia I; Giaquinto E; Leonessa V; Caputi M; Guarino C; Micillo E; Catena E; Altucci P
    Chemioterapia; 1986 Feb; 5(1):26-32. PubMed ID: 3955779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients.
    Rondanelli R; Dionigi RV; Regazzi MB; Maurelli M; Calvi M; Mapelli A
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):457-9. PubMed ID: 3536763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virulence factors in the colonization and persistence of bacteria in the airways.
    van Alphen L; Jansen HM; Dankert J
    Am J Respir Crit Care Med; 1995 Jun; 151(6):2094-9; discussion 2099-100. PubMed ID: 7767563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease.
    Desai H; Eschberger K; Wrona C; Grove L; Agrawal A; Grant B; Yin J; Parameswaran GI; Murphy T; Sethi S
    Ann Am Thorac Soc; 2014 Mar; 11(3):303-9. PubMed ID: 24423399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.
    van Zanten AR; Oudijk M; Nohlmans-Paulssen MK; van der Meer YG; Girbes AR; Polderman KH
    Br J Clin Pharmacol; 2007 Jan; 63(1):100-9. PubMed ID: 16869814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Infectious agents associated with exacerbations of chronic obstructive bronchopneumopathies and asthma attacks].
    Philit F; Etienne J; Calvet A; Mornex JF; Trillet V; Aymard M; Brune J; Cordier JF
    Rev Mal Respir; 1992; 9(2):191-6. PubMed ID: 1565831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the question of infectious aetiologies for multiple sclerosis, schizophrenia and the chronic fatigue syndrome and their treatment with antibiotics.
    Frykholm BO
    Med Hypotheses; 2009 Jun; 72(6):736-9. PubMed ID: 19269110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of exacerbations of COPD.
    Rosen MJ
    Am Fam Physician; 1992 Feb; 45(2):693-7. PubMed ID: 1739053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.